INMB
INmune Bio Inc
1.90$
+0.0%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 16 | Q4 16 | Q1 17 | Q2 17 | Q3 17 | Q4 17 | Q1 18 | Q2 18 | Q3 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | -100.0% | – | – | – | -63.6% | -99.9% | +349,900.0% | +1,064.3% | +0.0% | -90.2% | +512.5% | -1.0% | -60.8% | +21.1% | -6.5% | -34.9% | -50.0% | -100.0% | – | – | – | -100.0% | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | +100.0% | -7.1% | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -63.6% | -99.9% | +349,900.0% | +1,064.3% | +0.0% | -90.2% | +512.5% | -1.0% | -60.8% | +21.1% | -6.5% | -34.9% | -50.0% | – | – | – | – | – | – | – | – | – | – | |
| – | +2.2% | +104.6% | +12.7% | -28.7% | +479.4% | -61.2% | +176.2% | -30.8% | +159.2% | -80.3% | +189.2% | +297.5% | -25.8% | -8.5% | +13.9% | +161.7% | -21.3% | +34.0% | +79.2% | +46.1% | +8.4% | -39.0% | -2.8% | +23.2% | -33.9% | +21.2% | +0.4% | +44.3% | +0.4% | +44.7% | -18.9% | +42.7% | -27.0% | +3.9% | -24.0% | -15.8% | -52.3% | +56.3% | -77.9% | – | |
| – | +112.2% | +9.4% | +62.1% | +160.7% | -38.8% | +1,615.1% | +114.7% | -85.0% | +54.2% | +32.6% | -7.3% | +14.3% | -23.5% | -11.3% | -7.3% | +103.9% | -46.7% | +56.5% | +2.1% | +20.3% | -17.8% | +10.2% | -5.1% | +8.1% | -2.4% | +0.1% | +1.1% | +12.0% | -7.2% | -2.6% | +18.5% | -19.9% | -12.0% | +18.6% | -5.1% | +15.8% | +23.5% | -31.0% | +5.0% | – | |
| – | +148.5% | -77.3% | +440.5% | +86.2% | +39.2% | +564.6% | +116.9% | -75.1% | +22.1% | +1.6% | -77.6% | +619.8% | -24.4% | -10.3% | +0.7% | +128.7% | -33.2% | +41.4% | +44.0% | +37.9% | +1.7% | -27.8% | -3.6% | +17.8% | -23.9% | +12.6% | -0.1% | +32.7% | -1.9% | +31.2% | -10.6% | +24.5% | -22.9% | +5.2% | +146.8% | -69.7% | -27.1% | +6.3% | -74.4% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -98.0% | +5.9% | -37.3% | -32.3% | -40.8% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | -640.1% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | -304.8% | – | – | – | – | – | – | – | – | – | -98.0% | +5.9% | -37.3% | -32.3% | -40.8% | -5,773.5% | – | – | -174.3% | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | -640.1% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -131.3% | – | – | – | – | – | – | – | – | – | -10,262.2% | – | – | – | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.